At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
In Brief
A Phase 2 clinical trial evaluating Sodium oxybate for Spasmodic Dysphonia and Voice Tremor. Completed, enrolled 53 participants across 1 site.
Detailed Summary
The proposed research aims to determine brain abnormalities in patients with spasmodic dysphonia (SD) and voice tremor (VT) as the basis for characterization of central mechanisms underlying symptom improvement following the use of sodium oxybate, a novel oral medication for the treatment of ethanol-responsive dystonia. The proposed research is relevant to public health because the elucidation of disorder-specific mechanistic aspects of brain organization in SD vs. SD/VT is ultimately expected to lead to establishment of enhanced criteria for clinical management of these disorders, including differential diagnosis and treatment. Thus, the proposed research is relevant to the part of NIH's mission that pertains to developing fundamental knowledge that will help to reduce the burdens of human disability.
Study Details
Timeline
Interventions
Sodium oxybate